#marverick

Maverick: Time for plan G.

Y/c/s: Don’t you mean plan B?

Maverick: No, we tried plan B a long time ago. I had to skip over plan C due to technical difficulties.

Bob: What about plan D?

Maverick: Plan D was that desperate disguise attempt half an hour ago.

Phoenix: What about plan E?

Maverick: I’m hoping not to use it. Hangman dies in plan E.

And after the suicide mission, Bob gets super intrested in old aircrafts used by the Navy. So he just hyper fixates on it for a good long while.

While they are at lunch on the ship Bob just sits down infront of Mav, not even caring if he is talking to someone and being like

"I'm a little confused on how this would work in this aircraft, can you explain it?"

And Mav just falling in love because omg. This fucking kid comes up to him asking about an old aircraft cause he knows he's the expert. Mav proceeding to just explain to him everything he knows.

Bob being like "I learn how to do back seat if you wanna fly sometime"

Prof. Dr. Marylyn Addo is a German-born doctor of Ghanaian descent who specializes in creating vaccines used in the treatment of infectious diseases.

Her father is a Ghanaian doctor while her mother, on the other hand, is from Germany.

She is a German virologist who is a Professor and the German Center for Infection Research (DZIF) Head of Infectious Disease at the University Medical Center Hamburg-Eppendorf.

Dr. Addo has developed and tested vaccinations that protect people from Ebola virus disease and the MERS coronavirus EMC/2012.

She earned her diploma at the London School of Hygiene and Tropical Medicine, during which she researched Candida albicans transmission between HIV-positive people.

In 1999, she moved to Boston, where she specialised in infectious diseases at the Harvard Medical School.

When she was at Harvard University, Addo was made an Assistant Professor at the Ragon Institute and served as Associate Director of the Harvard University Center for AIDS Research.

She investigated the role of Indoleamine 2,3-dioxygenase (IDO) specific T cells as immune system regulators in patients with HIV-1.

In 2014, she was involved with the development of the preparation RVSV-EBOV, an experimental recombinant live vaccination that can be used against the Ebola virus disease.

Alongside the Ebola vaccination, Addo worked on a recombinant live vaccination to tackle the Middle East Respiratory Syndrome (MERS) vaccination and her vaccination was supported by the Coalition for Epidemic Preparedness Innovations.

She is currently leading the project that is geared towards helping to find and organise funding for the deadly coronavirus disease.